One Lambda Devyser Accept cfDNA Assay

Identify and quantify dd-cfDNA for post-transplant monitoring

Empower Your Transplant Program with a Simple and Robust NGS-based Donor-derived cell-free DNA (dd-cfDNA) Detection Assay

After a solid organ transplant, monitoring levels of dd-cfDNA can provide valuable insights into the organ's health and function. Allowing your laboratory to perform these tests on-site can empower your transplant program and provide better turnaround times for results. One Lambda™ Devyser™ Accept cfDNA, a non-invasive, cutting-edge single-tube NGS assay, provides precise and reliable results, enabling effective post-transplant monitoring and early detection of allograft injury.

Want to start tracking cell-free DNA in solid organ transplant patients for enhanced care?

Ask us about the One Lambda Devyser Accept cf-DNA assay.

What is the One Lambda Devyser
Accept cfDNA assay?

Minimally Invasive and Highly Robust Method for
Detecting dd-cfDNA

Accept cfDNA is an NGS assay designed to detect and analyze circulating dd-cfDNA in post-transplant human plasma samples. Its unique indel design allows for accurate discrimination between two genetically distinct donors per -recipient and reduces amplification and sequencing errors. Combined with an efficient workflow, Accept cfDNA is the ideal tool for post-transplant monitoring and early detection of graft injury.


How Does the One Lambda Devyser
Accept cfDNA Assay Work?

Efficient Workflow and Reliable Results for
Post-Transplant Monitoring

The One Lambda Devyser Accept cfDNA assay was developed in conjunction with a nephrologist to deliver efficiency and ease of use with minimal hands-on time. Labs can receive next-day results from sample to report allowing for timely and accurate diagnoses that can improve clinician decision-making. Our dedicated software simplifies data analysis and bioinformatics capabilities, allowing for easy patient tracking in a single location. With the ability to import analysed data into Histotrac, all information is consolidated, providing clear visibility of trends.

 

Assay Key Features & Benefits


  • Highly Sensitive: Enabling the detection of cfDNA at levels as low as 0.1% to detect injury earlier.
  • Robust Indel Design: Utilizing 50 highly informative and population-independent indel markers, the assay detects and differentiates between two genetically distinct donors for each recipient.
  • Unified Workflow: Simplify your laboratory processes with a streamlined workflow for both screening and monitoring assays with less than 45 minutes hands-on time.
  • Straightforward Data Analysis: The user-friendly, dedicated software simplifies data analysis and bioinformatics, and the built-in quality controls ensure confidence in results.
Perform post-transplant monitoring with ease and confidence using One Lambda Devyser Accept cfDNA.
Ask about our advanced cell-free-DNA testing solution today.

Advanced Molecular Transplant Monitoring Solutions with The Devyser and Thermo Fisher Scientific Partnership

The partnership between Devyser and Thermo Fisher Scientific combines expertise and resources to offer enhanced and cutting-edge molecular transplant monitoring capabilities to transplant programs, HLA labs, and transplant clinicians. Backed by Thermo Fisher Scientific's robust commercial infrastructure, our collaboration ensures reliable, accurate, and high-quality testing solutions for healthcare providers worldwide.

Explore Product Details

One lambda Devyser Accept cfDNA Assay
Targeted NGS assays that utilize Indel markers for monitoring donor-derived cell-free DNA (dd-cfDNA) in plasma samples. For Use on Illumina MiSeq Systems
Advyser Solid Organs Software
The software analyzes NGS data generated with an Illumina sequencer: Screening of informative markers and monitoring of donor-derived cell-free DNA (dd-cfDNA) in plasma samples
Disclaimers

Product is CE marked but not 510(k)-cleared and not available for sale in the U.S. Availability of product in each country depends on local regulatory marketing authorization status.